Product Pipeline: Bone Marrow and Aplastic Anemia Therapy - A personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. Fat stem cell based product to treat bone marrow that has been damaged Bone marrow damage occurs from radiation, chemo, or chronic conditions Uses animal’s own fat as source of endothelial cells to heal damaged bone marrow Tox studies have been successfully completed by Regen BioPharma Inc. the licensor of this technology to Zander Therapeutics. Aims to provide “natural” replacement to synthetic cytokines United States Food and Drug Administration Investigational New Drug Application (IND #15376, status cleared for use in humans by Regen BioPharma Inc. -- licensor to Zander Therapeutics Inc.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.